Clinical adverse effects of natalizumab: Protocol for a meta-analysis of randomized double-blind placebo-controlled clinical trails

BACKGROUND: Natalizumab (NAT), a humanized monoclonal antibody, which binds in both α(4)β(1) integrins and α(4)β(7) integrins, is approved for the treatment of multiple sclerosis (MS) and Crohn's disease (CD). An uncommon but serious adverse event from NAT treatment is known as progressive mult...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hao, Shi, Fang-Hong, Huang, Shi-Ying, Zhang, Shun-Guo, Gu, Zhi-Chun, Wei, Ji-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076155/
https://www.ncbi.nlm.nih.gov/pubmed/29995817
http://dx.doi.org/10.1097/MD.0000000000011507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076155/
https://www.ncbi.nlm.nih.gov/pubmed/29995817
http://dx.doi.org/10.1097/MD.0000000000011507

Ejemplares similares